Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APAF1 | O14727 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.49 |
| ▸ | FDPS | P14324 | 1/20 | 0.49 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.46 |
| ▸ | AGER | Q15109 | 4/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 4/20 | 0.45 |
| ▸ | TNF | P01375 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | HTT | P42858 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9180561 | 1.00 | APAF1 (0.51) | APAF1TDP1GGPS1FDPSASAH1 | |
| SCHEMBL28879025 | 1.00 | APAF1 (0.51) | APAF1TDP1GGPS1FDPSASAH1 | |
| SCHEMBL1992186 | 1.00 | APAF1 (0.51) | APAF1TDP1GGPS1FDPSASAH1 | |
| SCHEMBL22189059 | 0.89 | APAF1 (0.51) | APAF1TDP1GGPS1FDPSAGER | |
| SCHEMBL27659956 | 0.86 | AGER (0.56) | APAF1TDP1GGPS1FDPSASAH1 | |
| SCHEMBL8177049 | 0.86 | APAF1 (0.49) | APAF1TDP1GGPS1FDPSASAH1 | |
| SCHEMBL9186319 | 0.82 | LMNA (0.43) | CYP11B1CYP11B2TNFLMNASMN1; SMN2 | |
| SCHEMBL9185719 | 0.82 | LMNA (0.43) | TDP1GGPS1FDPSCYP11B1CYP11B2 | |
| SCHEMBL16097150 | 0.80 | TDP1 (0.68) | TDP1CYP11B1CYP11B2TNFLMNA | |
| SCHEMBL9038701 | 0.80 | TDP1 (0.68) | TDP1CYP11B1CYP11B2TNFLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8399422-B2 | Compositions for transfection of oligonucleotides active for gene silencing and their biological and therapeutical applications | POLYPLUS-TRANSFECTION (FR) | 2013-03-19 | — | — | US | disclosed |
| US-8399422-B2 | Compositions for transfection of oligonucleotides active for gene silencing and their biological and therapeutical applications | POLYPLUS-TRANSFECTION (FR) | 2013-03-19 | — | — | US | disclosed |
| CN-101631553-B | Compositions for transfection of oligonucleotides with gene silencing activity | POLYPLUS TRANSFECTION SA FR | 2012-10-17 | — | — | CN | disclosed |
| EP-2004156-B1 | COMPOSITIONS FOR TRANSFECTION OF OLIGONUCLEOTIDES ACTIVE FOR GENE SILENCING AND THEIR BIOLOGICAL AND THERAPEUTICAL APPLICATIONS | POLYPLUS TRANSFECTION SA (FR) | 2011-01-26 | — | — | EP | disclosed |
| US-20100048672-A1 | COMPOSITIONS FOR TRANSFECTION OF OLIGONUCLEOTIDES ACTIVE FOR GENE SILENCING AND THEIR BIOLOGICAL AND THERAPEUTICAL APPLICATIONS | POLYPLUS-TRANSFECTION (FR) | 2010-02-25 | — | — | US | disclosed |
| US-20100048672-A1 | COMPOSITIONS FOR TRANSFECTION OF OLIGONUCLEOTIDES ACTIVE FOR GENE SILENCING AND THEIR BIOLOGICAL AND THERAPEUTICAL APPLICATIONS | POLYPLUS-TRANSFECTION (FR) | 2010-02-25 | — | — | US | disclosed |
| CN-101631553-A | Compositions for transfection of oligonucleotides with gene silencing activity and biological and therapeutic applications thereof | POLYPLUS TRANSFECTION SA | 2010-01-20 | — | — | CN | disclosed |
| EP-2004156-A2 | COMPOSITIONS FOR TRANSFECTION OF OLIGONUCLEOTIDES ACTIVE FOR GENE SILENCING AND THEIR BIOLOGICAL AND THERAPEUTICAL APPLICATIONS | Polyplus-Transfection SA (FR) | 2008-12-24 | — | — | EP | disclosed |
| WO-2008004058-A2 | COMPOSITIONS FOR TRANSFECTION OF OLIGONUCLEOTIDES ACTIVE FOR GENE SILENCING AND THEIR BIOLOGICAL AND THERAPEUTICAL APPLICATIONS | POLYPLUS-TRANSFECTION SA (FR) | 2008-01-10 | — | — | WO | disclosed |
| WO-2008004058-A2 | COMPOSITIONS FOR TRANSFECTION OF OLIGONUCLEOTIDES ACTIVE FOR GENE SILENCING AND THEIR BIOLOGICAL AND THERAPEUTICAL APPLICATIONS | POLYPLUS-TRANSFECTION SA (FR) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048672-A1 | COMPOSITIONS FOR TRANSFECTION OF OLIGONUCLEOTIDES ACTIVE FOR GENE SILENCING AND THEIR BIOLOGICAL AND THERAPEUTICAL APPLICATIONS | C1R, C1S, C3AR1 | APAF1 1160/4885TDP1 3791/4885GGPS1 1463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.